Table 3.
CD8+ T cell epitopes identified in this study
| CD8+ peptide (amino acid position) | Sequence | No. of responding patients | ELISPOT frequencya | Source or reference (HLA restrictionb) |
|---|---|---|---|---|
| M 26 (126–140) | WILRHPGFTMMAAIL | 1 | 17.5 | This study |
| Env 21 (101–115) | WGNGCGLFGKGGIVT | 1 | In vitroc | This study |
| Env 41 (201–215) | MENKAWLVHRQWFLD | 2 | 20.3 | 12 (HLA B*3701) |
| Env 83 (411–425) | RMAILGDTAWDFGSL | 1 | 64.5 | 12 (HLA B*07) |
| Env 92 (456–470) | KILIGVIITWIGMNS | 1 | 17.5 | This study |
| NS1 33 (161–175) | GVFTTNIWLKLKEKQ | 1 | In vitro | This study |
| NS1 39 (191–205) | NRAVHADMGYWIESA | 1 | 8.5 | This study |
| NS2A 6 (26–40) | RVGTKHAILLVAVSF | 1 | 46 | This study |
| NS2A 11 (51–65) | RDLGRVMVMVGATMT | 3 | 118.7 | This study (HLA A*0101 or C*0602) |
| NS2B 22 (106–120) | ISGLFPVSIPITAAA | 1 | 39.5 | This study |
| NS3 18 (86–100) | EGEWKEGEEVQVLAL | 1 | 24 | This study |
| NS3 27 (131–145) | SPGTSGSPIIDKKGK | 6 | 22.5 | 7 (HLA A*1101) |
| NS3 41 (201–215) | KRYLPAIVREAIKRG | 2 | 26.6 | This study (HLA A*3101) |
| NS3 45 (221–235) | LAPTRVVAAEMEEAL | 1 | 15.5 | 27 (HLA B*07) |
| NS3 47 (231–245) | MEEALRGLPIRYQTP | 1 | 363 | 12 |
| NS3 51 (251–265) | HTGREIVDLMCHATF | 3 | 38.7 | 28 |
| NS3 61 (301–315) | STRVEMGEAAGIFMT | 1 | 9.5 | 12 (HLA B*4006) |
| NS3 68 (336–350) | EREIPERSWNSGHEW | 6 | 54.4 | This study (HLA B*5801) |
| NS3 100 (496–510) | DNINTPEGIIPSMFE | 4 | 233.5 | 12 (HLA B*35) |
| NS3 106 (526–540) | RGEARKTFVDLMRRG | 1 | 11.5 | 29 |
| NS3 108 (536–550) | LMRRGDLPVWLAYRV | 1 | In vitro | 12 (HLA B*5502) |
| NS3 111 (551–565) | AAEGINYADRRWCFD | 2 | 18.5 | 12 (HLA A*24) |
| NS3 120 (596–610) | LDARIYSDPLALKEF | 2 | 20.3 | This study (HLA A*2402) |
| NS4B 31 (151–165) | TVIDLDPIPYDPKFE | 1 | 60 | This study |
| NS4B 39 (191–205) | CEALTLATGPISTLW | 4 | 10.5 | This study |
| NS5 24 (116–130) | MSTYGWNLVRLQSGV | 1 | 111.5 | This study |
| NS5 33 (161–175) | TLRVLNLVENWLNNN | 1 | 19.5 | This study |
| NS5 59 (291–305) | SWHYDQDHPYKTWAY | 4 | 165.4 | 29 |
| NS5 61 (301–315) | KTWAYHGSYETKQTG | 1 | 9.5 | 29 |
| NS5 66 (326–340) | RLLTKPWDVVPMVTQ | 1 | In vitro | 29 (HLA B*5502) |
| NS5 69 (341–355) | MAMTDTTPFGQQRVF | 4 | 152 | This study (HLA A*6801 or B*3503) |
| NS5 78 (386–400) | GKKKTPRMCTREEFT | 1 | 34.5 | This study |
| NS5 113 (561–575) | HKKLAEAIFKLTYQN | 2 | 10.5 | This study |
| NS5 152 (756–770) | KSYAQMWSLMYEHRR | 1 | 60 | This study |
| NS5 176 (876–890) | NEEYTDYMPSMKRFR | 3 | 78.3 | This study |
a
ELISPOT frequencies are expressed as SPC/105 cells, and mean values are shown when n > 1.
b
HLA restriction is shown in boldface when it was identified in this study.
c
Peptides were identified only after in vitro expansion of T cells.